公开(公告)号：US20230235365A1

公开(公告)日：2023-07-27

申请号：US18087673

申请日：2022-12-22

Applicant: ReNAgade Therapeutics Management Inc.

Inventor： Alim Ladha ,  Vladimir Presnyak ,  Brian Goodman ,  Mario Rodriguez Mestre ,  Devin Scott Quinlan ,  Muthusamy Jayaraman ,  Stephen Scully

IPC: C12N15/90 ,  C12N15/11 ,  C12N9/22 ,  C12N9/12

CPC classification number: C12N15/907 ,  C12N15/11 ,  C12N9/22 ,  C12N9/1276 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2800/80

Abstract: Disclosed are engineered retrons and methods of use such as to modify the genome of a host (e.g., mammalian) cell by delivering the engineered retron or the encoded ncRNA in vitro or in vivo to the host (e.g., mammalian) cell.

公开(公告)号：US12054739B2

公开(公告)日：2024-08-06

申请号：US18472824

申请日：2023-09-22

Applicant: ReNAgade Therapeutics Management Inc.

Inventor： Alim Ladha ,  Vladimir Presnyak ,  Inna Shcherbakova ,  Brian Goodman ,  Mario Rodriguez Mestre ,  Devin Scott Quinlan ,  Muthusamy Jayaraman ,  Stephen Scully

IPC: C12N9/22 ,  C12N9/12 ,  C12N15/11 ,  C12N15/90

CPC classification number: C12N15/907 ,  C12N9/1276 ,  C12N9/22 ,  C12N15/11 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2800/80

Abstract: Disclosed are engineered retrons and methods of use such as to modify the genome of a host (e.g., mammalian) cell by delivering the engineered retron or the encoded ncRNA in vitro or in vivo to the host (e.g., mammalian) cell.

公开(公告)号：US20240175058A1

公开(公告)日：2024-05-30

申请号：US18472824

申请日：2023-09-22

Applicant: ReNAgade Therapeutics Management Inc.

Inventor： Alim Ladha ,  Vladimir Presnyak ,  Inna Shcherbakova ,  Brian Goodman ,  Mario Rodriguez Mestre ,  Devin Scott Quinlan ,  Muthusamy Jayaraman ,  Stephen Scully

IPC: C12N15/90 ,  C12N9/12 ,  C12N9/22 ,  C12N15/11

CPC classification number: C12N15/907 ,  C12N9/1276 ,  C12N9/22 ,  C12N15/11 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2800/80

Abstract: Disclosed are engineered retrons and methods of use such as to modify the genome of a host (e.g., mammalian) cell by delivering the engineered retron or the encoded ncRNA in vitro or in vivo to the host (e.g., mammalian) cell.

公开(公告)号：US20240130969A1

公开(公告)日：2024-04-25

申请号：US18521172

申请日：2023-11-28

Applicant: ReNAgade Therapeutics Management Inc.

Inventor： Muthusamy Jayaraman ,  Ciaran Lawlor ,  Brian Goodman

IPC: A61K9/127 ,  A61K9/51 ,  A61K31/7088

CPC classification number: A61K9/1271 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/7088

Abstract: The present disclosure provides pharmaceutical compositions comprising lipid nanoparticles capable of delivering polynucleotide payloads to target non-liver organs.

公开(公告)号：US11866728B2

公开(公告)日：2024-01-09

申请号：US18087673

申请日：2022-12-22

Applicant: ReNAgade Therapeutics Management Inc.

Inventor： Alim Ladha ,  Vladimir Presnyak ,  Inna Shcherbakova ,  Brian Goodman ,  Mario Rodriguez Mestre ,  Devin Scott Quinlan ,  Muthusamy Jayaraman ,  Stephen Scully

IPC: C12N15/11 ,  C12N15/90 ,  C12N9/22 ,  C12N9/12

CPC classification number: C12N15/907 ,  C12N9/1276 ,  C12N9/22 ,  C12N15/11 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2800/80

Abstract: Disclosed are engineered retrons and methods of use such as to modify the genome of a host (e.g., mammalian) cell by delivering the engineered retron or the encoded ncRNA in vitro or in vivo to the host (e.g., mammalian) cell.